welcome to im department meeting!
DESCRIPTION
Welcome to IM Department Meeting!. Gadolinium Based Contrast Exposure and Risk of Nephrogenic Systemic Fibrosis. Tonight’s Facilitators: Barbara Doerr, DO William Myers, DO Staci Smith, DO Michelle Cacek, DO. Nephrogenic Systemic Fibrosis (NSF). - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Welcome to IM Department Meeting!](https://reader036.vdocument.in/reader036/viewer/2022081514/56816022550346895dcf2467/html5/thumbnails/1.jpg)
Welcome to IM Department Meeting!
Gadolinium Based Contrast Exposure and Risk of Nephrogenic Systemic Fibrosis
Tonight’s Facilitators:Barbara Doerr, DOWilliam Myers, DOStaci Smith, DOMichelle Cacek, DO
![Page 2: Welcome to IM Department Meeting!](https://reader036.vdocument.in/reader036/viewer/2022081514/56816022550346895dcf2467/html5/thumbnails/2.jpg)
Nephrogenic Systemic Fibrosis (NSF)o originally named nephrogenic fibrosing
dermopathy (NFD)o manifestations initially thought to be
confined to the skino systemic fibrosis on autopsy (NSF)
oskeletal muscles ,diaphragm ,pleura ,dura mater, pericardium & myocardium
![Page 3: Welcome to IM Department Meeting!](https://reader036.vdocument.in/reader036/viewer/2022081514/56816022550346895dcf2467/html5/thumbnails/3.jpg)
Nephrogenic Systemic Fibrosis (NSF)
o predominately in pts with acute kidney injury or severely impaired renal function o CrCl less than 30
o no predilection for age, race, gender ,or location
o typically middle aged ptso reported in 8 yo children, as well as elderly
![Page 4: Welcome to IM Department Meeting!](https://reader036.vdocument.in/reader036/viewer/2022081514/56816022550346895dcf2467/html5/thumbnails/4.jpg)
What’s the risk?o risk of NSF estimated at 4.3 cases per 1,000
dialysis patients per yearo about 2.4 % for each time a CKD pt is
exposed to gadoliniumo balancing benefit and risko majority of pts who receive Gd do not
develop NSF
![Page 5: Welcome to IM Department Meeting!](https://reader036.vdocument.in/reader036/viewer/2022081514/56816022550346895dcf2467/html5/thumbnails/5.jpg)
What’s the issue with NSF?o avoidance of GBCA’s o limited radiological studies
o roadblocks to specific dxo litigation opportunities
![Page 6: Welcome to IM Department Meeting!](https://reader036.vdocument.in/reader036/viewer/2022081514/56816022550346895dcf2467/html5/thumbnails/6.jpg)
September 12, 2007
![Page 7: Welcome to IM Department Meeting!](https://reader036.vdocument.in/reader036/viewer/2022081514/56816022550346895dcf2467/html5/thumbnails/7.jpg)
Boxed Warningo Gadolinium based contrast agents
increase risk of NSF in pts with:o acute and chronic renal failure (GFR <
30)o acute renal insuffciency of any severity
due to hepatorenal syndrome or in perioperative liver transplant period
![Page 8: Welcome to IM Department Meeting!](https://reader036.vdocument.in/reader036/viewer/2022081514/56816022550346895dcf2467/html5/thumbnails/8.jpg)
What is Gadolinium?o nonionic, hyperosmolar (650 mosmol/kg)
contrast agento metal with powerful magnetic properties o contrast for MR imaging or MR angiographyo chelates are excreted exclusively by the
kidney
![Page 9: Welcome to IM Department Meeting!](https://reader036.vdocument.in/reader036/viewer/2022081514/56816022550346895dcf2467/html5/thumbnails/9.jpg)
Gadolinium Half Lifeo 1.3 hrs if healthyo 10 hrs at GFR of 20 - 40 mL/mino 34 hrs if ESRDo 1.9 - 2.6 hrs if HD follows administration
![Page 10: Welcome to IM Department Meeting!](https://reader036.vdocument.in/reader036/viewer/2022081514/56816022550346895dcf2467/html5/thumbnails/10.jpg)
Gadolinium Based Contrast Agentso Omniscan
o launched in the U.S. in 1993 by GEo Magnevisto MultiHanceo OptiMARKo ProHance
![Page 11: Welcome to IM Department Meeting!](https://reader036.vdocument.in/reader036/viewer/2022081514/56816022550346895dcf2467/html5/thumbnails/11.jpg)
Risk factors for NSFo renal impairmento hypercoagulable stateo thrombotic eventso recent vascular studyo transplant failure
![Page 12: Welcome to IM Department Meeting!](https://reader036.vdocument.in/reader036/viewer/2022081514/56816022550346895dcf2467/html5/thumbnails/12.jpg)
Signs and Symptoms of NSFo burning skino itchy skino swelling o tight and hard skin o red or dark skin
patcheso contractures
o stiffness in joints o trouble moving
extremities o pain deep in the boneso muscle weaknesso “woody” feel of skino yellow scleral plaques
![Page 13: Welcome to IM Department Meeting!](https://reader036.vdocument.in/reader036/viewer/2022081514/56816022550346895dcf2467/html5/thumbnails/13.jpg)
NSF Upper Extremityo thick, hardened
skin
o brawny hyperpigmentation
o distinct papules
o subcutaneous nodules
![Page 14: Welcome to IM Department Meeting!](https://reader036.vdocument.in/reader036/viewer/2022081514/56816022550346895dcf2467/html5/thumbnails/14.jpg)
NSF Upper Extremityo soft-tissue swelling o flexion contractures of hand
![Page 15: Welcome to IM Department Meeting!](https://reader036.vdocument.in/reader036/viewer/2022081514/56816022550346895dcf2467/html5/thumbnails/15.jpg)
o slightly raised and erythematous nodular plaqueso linear, confluent regions of fibrosis
NSF
![Page 16: Welcome to IM Department Meeting!](https://reader036.vdocument.in/reader036/viewer/2022081514/56816022550346895dcf2467/html5/thumbnails/16.jpg)
Differential Diagnosis
o scleroderma / systemic sclerosis o eosinophilic fasciitis o eosinophilia–myalgia syndrome
![Page 17: Welcome to IM Department Meeting!](https://reader036.vdocument.in/reader036/viewer/2022081514/56816022550346895dcf2467/html5/thumbnails/17.jpg)
Differential Diagnosiso Unlike scleroderma
o NSF spares the face o lacks the serologic markers of
sclerodermao symmetrical lesions
oprefers trunk and extremities
![Page 18: Welcome to IM Department Meeting!](https://reader036.vdocument.in/reader036/viewer/2022081514/56816022550346895dcf2467/html5/thumbnails/18.jpg)
Punch Biopsy : Skin
widening of subcutaneous septae w/ thick collagen bundles
![Page 19: Welcome to IM Department Meeting!](https://reader036.vdocument.in/reader036/viewer/2022081514/56816022550346895dcf2467/html5/thumbnails/19.jpg)
Histological Findings and Pathogenesis
o thick collagen bundles with surrounding clefts
o mucin depositiono increased fibrocytes and elastic fiberso increased factor XIIIa and mononucleated
cells
![Page 20: Welcome to IM Department Meeting!](https://reader036.vdocument.in/reader036/viewer/2022081514/56816022550346895dcf2467/html5/thumbnails/20.jpg)
Topic Development: PICOo P
Patient Populationo I
Intervention or Exposureo C
Comparison Interventiono O
Outcome
![Page 21: Welcome to IM Department Meeting!](https://reader036.vdocument.in/reader036/viewer/2022081514/56816022550346895dcf2467/html5/thumbnails/21.jpg)
Question ???o What degree of kidney disease should
we not use gadolinium based contrast agents ?
![Page 22: Welcome to IM Department Meeting!](https://reader036.vdocument.in/reader036/viewer/2022081514/56816022550346895dcf2467/html5/thumbnails/22.jpg)
Articleo Nephrogenic Fibrosing Dermopathy/
Nephrogenic Systemic Fibrosis: Report of a New Case with Literature Review
o Daram, et al. AJKD, Vol 46, No 4, 2005, pp 754-759.
![Page 23: Welcome to IM Department Meeting!](https://reader036.vdocument.in/reader036/viewer/2022081514/56816022550346895dcf2467/html5/thumbnails/23.jpg)
Evidence Based Medicineo Nephrogenic Fibrosing
Dermopathy /Nephrogenic Systemic Fibrosis: Report of a New Case with Literature Review
o Daram ,et al. o AJKD 2005
![Page 24: Welcome to IM Department Meeting!](https://reader036.vdocument.in/reader036/viewer/2022081514/56816022550346895dcf2467/html5/thumbnails/24.jpg)
Introduction- NSF: Report of a New Case
o first cases of NSF recognized in 2000o renal dysfunction pts
o regardless of causeo not just HD pts, PD pts as well
o other associations:o vascular sxo vascular thrombosiso scleral plaques
![Page 25: Welcome to IM Department Meeting!](https://reader036.vdocument.in/reader036/viewer/2022081514/56816022550346895dcf2467/html5/thumbnails/25.jpg)
The Patient: NSF: Report of a New Case
o 39 yo AAM o ESRD on HD d/t HTN for 8 yrso multiple medical problems
oantiphospholipid ab syndromeo no other rheumatologic history o 3 yrs before hospital admission
ostiff fingers and armsothickening skin on calves and thighsorapid progression to contractures
![Page 26: Welcome to IM Department Meeting!](https://reader036.vdocument.in/reader036/viewer/2022081514/56816022550346895dcf2467/html5/thumbnails/26.jpg)
The Patient- NSF: Report of a New Caseo pt’s lab data -p 755o fibrosis around
translumbar HD catho pt expired after 45
min of ACLS
o autopsy resultso extensive fibrosiso plaque like changes
across chest, extremities
o contractureso thickened pleurao dense collagenous
bandso fibrotic cardiac tissue
![Page 27: Welcome to IM Department Meeting!](https://reader036.vdocument.in/reader036/viewer/2022081514/56816022550346895dcf2467/html5/thumbnails/27.jpg)
NSF: Report of a New Case
o taut, waxy appearanceo cobblestone pattern o fig 1B
![Page 28: Welcome to IM Department Meeting!](https://reader036.vdocument.in/reader036/viewer/2022081514/56816022550346895dcf2467/html5/thumbnails/28.jpg)
NSF: Report of a New Case
o chest wall w/thick dermis
o dense white fibrous bands in septa
![Page 29: Welcome to IM Department Meeting!](https://reader036.vdocument.in/reader036/viewer/2022081514/56816022550346895dcf2467/html5/thumbnails/29.jpg)
NSF: Report of a New Case
haphazardly arranged collagen bundles w/ clefts
![Page 30: Welcome to IM Department Meeting!](https://reader036.vdocument.in/reader036/viewer/2022081514/56816022550346895dcf2467/html5/thumbnails/30.jpg)
NSF: Report of a New Case
o diaphragm sectiono fibrous bands o fibroblast like cells
![Page 31: Welcome to IM Department Meeting!](https://reader036.vdocument.in/reader036/viewer/2022081514/56816022550346895dcf2467/html5/thumbnails/31.jpg)
NSF: Report of a New Case
dendritic projections on CD34 cells CD45 RO cells
![Page 32: Welcome to IM Department Meeting!](https://reader036.vdocument.in/reader036/viewer/2022081514/56816022550346895dcf2467/html5/thumbnails/32.jpg)
Discussion- NSF: Report of a New Case
o NFD is not merely a cutaneous diseaseo systemic manifestations
omuscle, pleura, diaphragm, myo and pericardium
o initiating factors in NSFo tissue injuryo hypercoagulable state
![Page 33: Welcome to IM Department Meeting!](https://reader036.vdocument.in/reader036/viewer/2022081514/56816022550346895dcf2467/html5/thumbnails/33.jpg)
Discussion - NSF: Report of a New Case
o NSF involves aberrant fibrocyte recruitmento decrease EPO due to fibrogenic properties
o NO consistent treatment proven effective
![Page 34: Welcome to IM Department Meeting!](https://reader036.vdocument.in/reader036/viewer/2022081514/56816022550346895dcf2467/html5/thumbnails/34.jpg)
Articleo Nephrogenic Systemic Fibrosis After
Exposure to Gadolinium in Patients with Renal Failure
o Othersen, J. et al, Nephrology Dialysis Transplantation, Sept 21, 2007, p 1-7.
![Page 35: Welcome to IM Department Meeting!](https://reader036.vdocument.in/reader036/viewer/2022081514/56816022550346895dcf2467/html5/thumbnails/35.jpg)
Evidence Based Medicine
o Nephrogenic Systemic Fibrosis After Exposure to Gadolinium in Patients with Renal Failure
![Page 36: Welcome to IM Department Meeting!](https://reader036.vdocument.in/reader036/viewer/2022081514/56816022550346895dcf2467/html5/thumbnails/36.jpg)
NSF After Gadolinium Exposure
o Purpose:o analyze NSF incidence o association of NSF with gadolinium
exposure in CKD ptsoboth pre-dialysis and dialysis pts
o determine if increased gadolinium exposure increases NSF
![Page 37: Welcome to IM Department Meeting!](https://reader036.vdocument.in/reader036/viewer/2022081514/56816022550346895dcf2467/html5/thumbnails/37.jpg)
NSF After Gadolinium Exposure
o Methods:o 849 total pts in 5 yr time span (2001-2006)o Nephrology at Medical University of SC
odiscussed with Dermatologyo stratified by gadolinium exposure
o0, 1, or greater than 1o statistical association between NSF rate
and gad exposure o statistical association of increasing gad
exposure and NSF occurrence
![Page 38: Welcome to IM Department Meeting!](https://reader036.vdocument.in/reader036/viewer/2022081514/56816022550346895dcf2467/html5/thumbnails/38.jpg)
NSF After Gadolinium Exposure
o Methods:o CKD pts NOT on dialysiso 592 pts or 4% had CKD 3 – 4o 6,636 total pts received gad from 2004-
2006o skin bx w/ immunoperoxidase staining for
CD 34
![Page 39: Welcome to IM Department Meeting!](https://reader036.vdocument.in/reader036/viewer/2022081514/56816022550346895dcf2467/html5/thumbnails/39.jpg)
NSF After Gadolinium Exposure
o Results:o 849 total ptso 261 had 354 MRI scans
ow/ gadolinium (Omniscan)o1 time exposure in 191 ptso2 exposures in 53o3 exposures in 13o4 exposures in 5
![Page 40: Welcome to IM Department Meeting!](https://reader036.vdocument.in/reader036/viewer/2022081514/56816022550346895dcf2467/html5/thumbnails/40.jpg)
NSF After Gadolinium Exposure
Gadolinium Exposure
NSF Incidence
Never 0%
One time 1.1%
Greater than one time 2.9%
![Page 41: Welcome to IM Department Meeting!](https://reader036.vdocument.in/reader036/viewer/2022081514/56816022550346895dcf2467/html5/thumbnails/41.jpg)
NSF After Gadolinium Exposure
o Results: Pts on Dialysiso overall NSF rate 0.5% (4 of 261)o 1.5% risk of NSF after one gad exposureo 98.5% did not develop NSFo odds ratio 6.67 w/ one exposure
o44.5 odds ratio with multiple exposureso skin lesions appeared within 2-3 moo strong statistical association with NSF
and gadolinium exposure
![Page 42: Welcome to IM Department Meeting!](https://reader036.vdocument.in/reader036/viewer/2022081514/56816022550346895dcf2467/html5/thumbnails/42.jpg)
NSF After Gadolinium Exposure
o Results : CKD 3 – 4 ptso no patients discovered to have NSFo incidence estimated at <0.2%o possibly due to only 4% have CKD 3-4
![Page 43: Welcome to IM Department Meeting!](https://reader036.vdocument.in/reader036/viewer/2022081514/56816022550346895dcf2467/html5/thumbnails/43.jpg)
NSF After Gadolinium Exposure
o Conclusions:o NSF incidence is very lowo increased exposure leads to increased risko higher Ca, Phos, and Epo may be associated
with increased NSF incidenceo NO need for gad restriction in CKD 3- 4o monitor skin for 4-6 mo if gad is usedo consider dialysis immediately after exposureo kidney transplant therapy in future
![Page 44: Welcome to IM Department Meeting!](https://reader036.vdocument.in/reader036/viewer/2022081514/56816022550346895dcf2467/html5/thumbnails/44.jpg)
Concluding Pointso A
o Academic Detailingo R
o Reminderso E
o Enticementso A
o Audit
![Page 45: Welcome to IM Department Meeting!](https://reader036.vdocument.in/reader036/viewer/2022081514/56816022550346895dcf2467/html5/thumbnails/45.jpg)
Concluding Points: Academic Detailso Academic Detailing:
o Medical knowledgeoNSF
o Patient careo Communicationo OMM/OPP o Systems based practice
oPhysician interacts with healthcare systemo Practice based learning
oPhysicians maintain knowledge and skills to provide ongoing pt care
![Page 46: Welcome to IM Department Meeting!](https://reader036.vdocument.in/reader036/viewer/2022081514/56816022550346895dcf2467/html5/thumbnails/46.jpg)
Osteopathic Considerationso myofascial release
o indirect techniqueso whole body approach
![Page 47: Welcome to IM Department Meeting!](https://reader036.vdocument.in/reader036/viewer/2022081514/56816022550346895dcf2467/html5/thumbnails/47.jpg)
Osteopathy in Actiono NSF registry
o collects info about NSF pts from all over the world
o General Clinical Research Center at Yale University
o e-mail : registermc @juno.como CDC
o www.cdc.govo FDA
o 1-800-FDA-1088o www.FDA.gov
![Page 48: Welcome to IM Department Meeting!](https://reader036.vdocument.in/reader036/viewer/2022081514/56816022550346895dcf2467/html5/thumbnails/48.jpg)
Systems Based Practice o acute NSF: 58089o chronic NSF: 5829o include CKD staging: 585.-o principal procedure
o MRI imaging: 8897
![Page 49: Welcome to IM Department Meeting!](https://reader036.vdocument.in/reader036/viewer/2022081514/56816022550346895dcf2467/html5/thumbnails/49.jpg)
Systems Based Practiceo Cerebral a.
occlusion w/ cerebral infarction
DRG: 43491
$5,246.24 Medicare
o Cerebral a. occlusion w/ cerebral infarction
plus acute NSF DRG: 43491, 58089
$7,877.25 Medicare
![Page 50: Welcome to IM Department Meeting!](https://reader036.vdocument.in/reader036/viewer/2022081514/56816022550346895dcf2467/html5/thumbnails/50.jpg)
Reminders
o Carepath in futureo screening baseline kidney fxn / sizeo acute kidney injury vs CKDo CrCl –when not to use gadoliniumo follow-up labs after gadolinium useo when to dialyze ESRD pts if GBCA used
![Page 51: Welcome to IM Department Meeting!](https://reader036.vdocument.in/reader036/viewer/2022081514/56816022550346895dcf2467/html5/thumbnails/51.jpg)
Enticements/ Systems Based Practiceo MRI imaging: DRG 8897o MRI brain w/ contrast: $3,692o MRI brain w/o contrast: $2,255o MRI thoracic/lumbar spine w/ contrast :
$2,465o MRI thoracic/lumbar w/o contrast: $2,144
![Page 52: Welcome to IM Department Meeting!](https://reader036.vdocument.in/reader036/viewer/2022081514/56816022550346895dcf2467/html5/thumbnails/52.jpg)
Audito How can we measure outcomes and
progress?
o Practice habits changed in the future?
![Page 53: Welcome to IM Department Meeting!](https://reader036.vdocument.in/reader036/viewer/2022081514/56816022550346895dcf2467/html5/thumbnails/53.jpg)
Conclusions : Take Home Points
o interest of pt safetyo balance benefits and risks of GBCA’s
o screen all pts with labs and historyo GBCA’s should NOT be used if CrCl
<30o careful consideration if CrCl <60
o alternative imaging methods
![Page 54: Welcome to IM Department Meeting!](https://reader036.vdocument.in/reader036/viewer/2022081514/56816022550346895dcf2467/html5/thumbnails/54.jpg)
Conclusions: Take Home Pointso monitor for skin manifestations after GBCAo follow labs after administration o do not exceed recommended dose
o 0.1-0.2 mmol/kgo allow time for elimination before
readministration
![Page 55: Welcome to IM Department Meeting!](https://reader036.vdocument.in/reader036/viewer/2022081514/56816022550346895dcf2467/html5/thumbnails/55.jpg)
Please Join Us Next Montho IM Journal Club
o presented by Dr. Bryano laryngeal reflux and proton pump
inhibitors
![Page 56: Welcome to IM Department Meeting!](https://reader036.vdocument.in/reader036/viewer/2022081514/56816022550346895dcf2467/html5/thumbnails/56.jpg)
Referenceso Nephrogenic Fibrosing Dermopathy
/Nephrogenic Systemic Fibrosis: Report of a New Case with Literature Review.Daram ,et al. AJKD 2005.
o Nephrogenic Systemic Fibrosis After Exposure to Gadolinium in Patients with Renal Failure. Othersen, J. et al, Nephrology Dialysis Transplantation, Sept 21, 2007, p 1-7.
![Page 57: Welcome to IM Department Meeting!](https://reader036.vdocument.in/reader036/viewer/2022081514/56816022550346895dcf2467/html5/thumbnails/57.jpg)
Happy Halloween !!Trick or treat
![Page 58: Welcome to IM Department Meeting!](https://reader036.vdocument.in/reader036/viewer/2022081514/56816022550346895dcf2467/html5/thumbnails/58.jpg)
References• www.cdc.gov• www.fda.gov• Gadodiamide-Associated Nephrogenic
Systemic Fibrosis: Why Radiologists Should Be Concerned . Dale R. Broome et al. AJR 2007; 188:586-592.
• Adverse Reactions to Gadolinium Contrast Media: A Review of 36 Cases. Murphy,et al. AJR, Oct 1996:847-849.